Krystal Biotech, Inc. (KRYS)

Over the past six months, Krystal Biotech's stock price increased by 36.40%. As of April 7, 2026, the stock traded at $261.80, representing a 58.11% increase over the last 12 months and a 6.47% year-to-date return. Key events impacting the stock price include the release of Q4 and full year 2025 financial results, a KB407 clinical data update, presentations at healthcare conferences, analyst price target increases, and FDA designations for KB707 and KB111.

Demand for Krystal Biotech's products is generally not expected to exhibit significant seasonality due to the focus on rare and severe genetic diseases. Demand is typically driven by patient need and diagnosis rather than seasonal factors. However, there is some indication of seasonality in the implied volatility of KRYS stock, which tends to rise most in April and decline to its lowest levels in September, relating more to market trading activity and investor sentiment.

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs. Their flagship product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa (DEB) in the United States, Europe, and Japan. The company also has an extensive pipeline of product candidates in clinical and preclinical development, including treatments for Cystic Fibrosis, Alpha-1 Antitrypsin Deficiency, solid tumors, and aesthetic skin conditions.

Krystal Biotech's corporate office is located in Pittsburgh, Pennsylvania. They manufacture, market, and sell VYJUVEK in the United States, Germany, France, and Japan, possessing exclusive international rights for the product.

Krystal Biotech has maintained a strong brand reputation over the past year, driven by the successful commercialization of VYJUVEK and positive pipeline developments. The company is viewed as a "Strong Buy" by analysts. Positive events contributing to its reputation include robust VYJUVEK demand, international expansion, positive clinical updates, and strong financial performance. However, challenges include a decrease in net income for Q4 FY25, concerns about funding, and the inherent risks associated with gene therapy.

Krystal Biotech, Inc. has significant institutional ownership, with 339 institutional owners and shareholders holding approximately 86.67% of the company's shares. Individuals hold about 10.45%. Major institutional owners include Fmr Llc, BlackRock, Inc., and Avoro Capital Advisors LLC. Key individual owners include Suma Krishnan and Krish S. Krishnan, each owning 3.14 million shares.